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Advocates for state-level Medicaid expansion articulate a broad set of benefits designed to 
increase healthcare affordability, quality and access for a larger set of low-income residents. But, 
in some cases, medicaid expansion may result in cost shifting strategies that target not only 
privately insured and private-pay consumers, but also individuals that have specific chronic 
disease diagnoses. Our paper starts with a discussion of the overarching effects of state-level 
Medicaid expansion on cost, quality and access to health services. This discussion sets the stage 
for our primary point of interest, the effect of Medicaid expansion on chronic diagnoses, where 
treatment protocols are characterized by very inelastic demand. Because these diagnoses, in 
particular, bind patients to systematic, well-defined treatment protocols for the life of the patient, 
they are uniquely suited to targeted cost-shifting strategies that lay a disproportionate burden of 
Medicaid expansion costs at the feet of individuals that are already disadvantaged by a chronic 
diagnosis. Diabetes is a chronic diagnosis at the forefront of the U.S. policy discussion 
surrounding pharmaceutical industry reform, thus we take a deep dive into insulin pricing as an 
example of how medicaid expansion could cause increased cost shifting to occur. A research 
approach that targets specific diagnosis groups makes it easier to deconstruct the effects of 
Medicaid expansion on well-identified groups of healthcare system users. This framework 
provides a mechanism to explore specific "fairness" arguments associated with Medicaid 
expansion that target the inherent cost-shifting burdens of broadly focused healthcare policies. 
Our research finds that there is potential for a significant and disproportionate cost-shifting 
burden that unfairly targets patients with chronic disease diagnoses. 
































